Evaluation of quality of life and prognostic scales in patients with chronic obstructive pulmonary disease

Abstract

The aim of this study was assessment of vaccination effects on quality of life and main prognostic scores in COPD patients. Methods. The study involved 362 male patients with COPD. Vaccination was done using 13 valent conjugate pneumococcal vaccine Prevenar-13 (PCV13) and polyva-lent pneumococcal vaccine Pneumo-23 (PPV23). Quality of life was assessed using the Russian version of SRGQ and CAT questionnaire. Prognostic BODE, DOSE and ADO scores were calculated. Results. Vaccination with PCV13 and PPV23 was associated with improvement in quality of life in 1 year after vaccination, though this effect of PPV23 decreased to the 3rd year. Quality of life questionnaires help to assess the therapeutic strategy chosen both in early and delayed follow-up. BODE, DOSE, and ADO scores have demonstrated a reliable and statistically significant decrease in 1 year after vaccination; for PCV13, this effect maintained in 3 years after vaccination. Conclusion. Vaccination with PCV13 could reduce total 3-year healthcare expenses to 11,357 RUB (78%), partly due to long-term maintenance of the effect of vaccination. This is an important advantage of PCV13 over PPV23 both from economic and clinical points of view.